Table 2. Platelet function, reflecting the antiplatelet effect of aspirin, analyzed by platelet aggregation and serum thromboxane B 2 measurements ( n = 48 in both patient groups) .
| ET patients | CAD patients | ||||||
|---|---|---|---|---|---|---|---|
| Difference | Difference | Comparison a | p -Value b | ||||
| 1h | 24h | (24 vs. 1h) | 1h | 24h | (24 vs. 1h) | ET vs. CAD | |
| Thromboxane B 2 ; TXB 2 , (ng/mL) | |||||||
| 6.4 | 32.3 | 26.2 | 1.5 | 5.1 | 3.7 | 22.5 | < 0.0001 |
| (3.1–14.4) | (14.2–64.0) | (10.1–48.0) | (0.8–3.6) | (3.8–8.3) | (2.6–6.0) | ||
| Platelet aggregation ; AA, (AU*min) | |||||||
| 455 | 786 | 251 | 434 | 522 | 119.5 | 131 | 0.0003 |
| (258–615) | (474–934) | (99–362) | (266–595) | (400–696) | (52–192) | ||
Abbreviations: AA, arachidonic acid (ASPItest); AU*min, aggregation units * min.; CAD, coronary artery disease; ET, essential thrombocythemia; TXB2, thromboxane B2.
Data are shown as median (interquartile range).
a
Median of differences (CAD vs. ET); b Calculated using the Mann–Whitney U test.